Galectin Therapeutics (GALT) Payables (2010 - 2026)

Galectin Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Payables fell 54.36% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 54.36% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 45.66% from the prior year.
• Payables fell to $3.1 million in Q1 2026 per GALT's latest filing, from $3.3 million in the prior quarter.
• Across five years, Payables topped out at $9.1 million in Q3 2025 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Payables is $3.3 million (2025), against an average of $4.1 million.
• Across the five-year window, Payables soared 398.95% in 2022 and plunged 54.36% in 2026, its largest moves.
• Year by year, Payables stood at $4.0 million in 2022, then soared by 64.24% to $6.5 million in 2023, then declined by 6.25% to $6.1 million in 2024, then sank by 45.66% to $3.3 million in 2025, then decreased by 5.65% to $3.1 million in 2026.
• Per Business Quant, the three latest GALT Payables figures stand at $3.1 million (Q1 2026), $3.3 million (Q4 2025), and $9.1 million (Q3 2025).